4D MOLECULAR THERAPEUTICS IN's ticker is FDMT and the CUSIP is 35104E100. A total of 81 filers reported holding 4D MOLECULAR THERAPEUTICS IN in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $13,808,498 | -25.9% | 1,084,721 | +5.2% | 0.17% | -18.0% |
| Q2 2023 | $18,637,362 | +5.0% | 1,031,398 | -0.1% | 0.20% | +1.5% |
| Q1 2023 | $17,752,440 | -18.6% | 1,032,719 | +5.1% | 0.20% | -22.3% |
| Q4 2022 | $21,814,640 | +77.3% | 982,199 | -35.8% | 0.26% | +72.2% |
| Q3 2022 | $12,301,000 | +23.7% | 1,529,958 | +7.4% | 0.15% | +32.5% |
| Q2 2022 | $9,942,000 | -42.6% | 1,424,314 | +24.3% | 0.11% | -25.0% |
| Q1 2022 | $17,321,000 | -29.0% | 1,145,585 | +3.1% | 0.15% | -22.4% |
| Q4 2021 | $24,388,000 | -9.9% | 1,111,579 | +10.8% | 0.20% | -7.5% |
| Q3 2021 | $27,063,000 | +9.1% | 1,003,447 | -2.6% | 0.21% | +13.4% |
| Q2 2021 | $24,800,000 | -45.5% | 1,029,897 | -1.7% | 0.19% | -45.0% |
| Q1 2021 | $45,471,000 | +3.1% | 1,048,189 | -1.5% | 0.34% | -0.6% |
| Q4 2020 | $44,092,000 | – | 1,063,744 | – | 0.34% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BVF INC/IL | 4,007,413 | $68,887,429 | 2.52% |
| Opaleye Management Inc. | 314,000 | $5,397,660 | 1.62% |
| Deep Track Capital, LP | 2,278,107 | $39,160,659 | 1.61% |
| Casdin Capital, LLC | 1,070,000 | $18,393,300 | 1.52% |
| Eagle Health Investments LP | 437,911 | $7,527,690 | 1.46% |
| ACUTA CAPITAL PARTNERS, LLC | 104,753 | $1,800,704 | 1.33% |
| Octagon Capital Advisors LP | 499,996 | $8,594,931 | 1.24% |
| Soleus Capital Management, L.P. | 469,400 | $8,068,986 | 0.84% |
| Novo Holdings A/S | 700,000 | $12,033,000 | 0.79% |
| VIKING GLOBAL INVESTORS LP | 3,937,914 | $67,692,742 | 0.32% |